Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etomidate + fentanyl + lidocaine
- Development stage
- Phase 4
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Intravenous, Intrathecal
01
Overview
A combination of three medications used for procedural sedation and analgesia. Etomidate is a non-barbiturate hypnotic that acts at the GABA receptor level to produce anesthesia without significant cardiovascular depression[3][6]. Fentanyl is a fast-acting synthetic opioid that provides analgesia and helps reduce hypertensive and tachycardic responses to stimulation during procedures[4]. Lidocaine is a local anesthetic that can be used to enhance pain control.
02
Targets
GABA-B (Gamma-aminobutyric acid receptor type B)MOR (Mu opioid receptor)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on etomidate + fentanyl + lidocaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etomidate + fentanyl + lidocaine.